Russian pharmaceutical companies: scientific R&D evaluation methods as a factor of competitiveness in the context of pandemic

Nadezhda Mixajlovna Yarceva
Additional contact information
Nadezhda Mixajlovna Yarceva: Russian Foreign Trade Academy, Moscow, Russia

Russian Foreign Economic Journal, 2020, issue 7, 18-24

Abstract: The methods used in Russian accounting practices do not allow pharmaceutical companies to fully assess the intangible advantages that will allow them to compete in the market successfully. In accordance with the international approach, if proof of the effectiveness and safety of a new drug has already been obtained, the company can start including current costs in the cost of a new intangible asset as early as the third phase of research. As for the Russian rules, capitalization of development costs is possible only after execution of regulatory authority registration of a new drug.

Keywords: Evaluation of scientific research and development; intangible assets; pharmaceutical company; competitiveness. (search for similar items in EconPapers)
Date: 2020
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://repec.vavt.ru/RePEc/alq/rufejo/rfej_2020_07_18-24.pdf (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:alq:rufejo:rfej_2020_07_18-24

Access Statistics for this article

More articles in Russian Foreign Economic Journal from Russian Foreign Trade Academy Ministry of economic development of the Russian Federation Contact information at EDIRC.
Bibliographic data for series maintained by Irina Katolik ().